MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update
• Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the treatment of achromatopsia LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- …